| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA460: Adalimumab and dexamethasone for treating non-infectious uveitis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | dexamethasone (Ozurdex®) | |
| Formulation | 700 micrograms intravitreal implant | |
| Reference number | 864 | |
| Indication | Treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis |
|
| Company | Allergan Ltd | |
| BNF chapter | Eye | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 01/11/2011 | |
| Date of issue | 02/11/2011 | |
| NICE guidance | TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
|